Document is current
Any future updates will be listed below
-
Authors
Mathur, Ravi https://orcid.org/0000-0001-6785-0032
Fang, Fang https://orcid.org/0000-0001-9829-2934
Gaddis, Nathan
Hancock, Dana B. https://orcid.org/0000-0003-2240-3604
Cho, Michael H. https://orcid.org/0000-0002-4907-1657
Hokanson, John E.
Bierut, Laura J.
Lutz, Sharon M.
Young, Kendra https://orcid.org/0000-0002-8664-7635
Smith, Albert V.
,
Silverman, Edwin K.
Page, Grier P. https://orcid.org/0000-0003-2582-3786
Johnson, Eric O. https://orcid.org/0000-0002-8870-1949
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA044014)
- License Information
-
More Information
Article History
Received: 21 December 2021
Accepted: 18 July 2022
First Online: 11 August 2022
Competing interests
: E.K.S. has received institutional grant support from GlaxoSmithKline and Bayer. M.H.C. has received grant support from GSK and Bayer, and consulting or speaking fees from Illumina, Genentech, and AstraZeneca. All other authors have no competing interests.
